J&J's M1 Antagonist PIPE-307 Misses Primary Endpoint in Phase 2 MDD Trial, Second Setback for the Molecule
核心洞察
The Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder (搜索) failed to meet its primary MADRS efficacy endpoint at Day 5 versus placebo.
The M1 receptor (搜索) antagonist was well tolerated with no new safety signals, and Johnson & Johnson is still analyzing prespecified exploratory endpoint data.
The miss is the second Phase 2 failure for the molecule, following the VISTA trial in relapsing-remitting multiple sclerosis (搜索) in 2025.
Contineum Therapeutics (NASDAQ: CTNM) reported on September 14, 2026 that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 did not achieve its primary efficacy endpoint in adults with major depressive disorder (搜索) (MDD). The trial, which evaluated improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo, is the second mid-stage failure for the same molecule in less than a year.
JNJ-5120/PIPE-307 is a selective inhibitor of the muscarinic M1 receptor (搜索), a cholinergic target implicated in cognitive and mood regulation. The rationale for M1 antagonism in depression draws on evidence that excess cholinergic tone contributes to depressive states. The molecule is being developed by Johnson & Johnson under a global license and development agreement, with J&J holding sole discretion over further development in MDD, multiple sclerosis or other indications.
Trial Design and Results
MOONLIGHT-1 was a randomized, double-blind, multicenter, placebo-controlled proof-of-concept trial evaluating the efficacy, safety and tolerability of JNJ-5120/PIPE-307 as monotherapy in adult participants with MDD. Investigators randomized 107 patients to receive one of two dosing regimens of the drug or placebo. At Day 5, patients on JNJ-5120 showed no statistically significant improvement on the MADRS compared with those receiving placebo, causing the study to miss its primary endpoint. The drug was well tolerated, with no new safety signals reported. Further information on the trial is available at ClinicalTrials.gov under identifier NCT06785012.
Contineum said Johnson & Johnson continues to evaluate the trial data, including results from prespecified exploratory endpoints, and will assess the totality and clinical relevance of the findings before deciding on next steps for the candidate. The New Jersey-based pharmaceutical company has not indicated whether it will continue development.
A Second Phase 2 Disappointment
The MOONLIGHT-1 failure comes roughly ten months after Contineum's own mid-stage VISTA trial of PIPE-307 in relapsing-remitting multiple sclerosis (搜索) missed its prespecified primary and secondary efficacy endpoints. That November 2025 readout triggered a selloff in Contineum shares, and analysts had already flagged the depression study as high-risk.
William Blair analysts removed JNJ-5120 from their financial model following the latest miss, extinguishing what had been a 35% probability of success assigned before the readout. "We had always viewed the study as risky, especially considering the risky nature of placebo-controlled studies in MDD, where placebo responses have eroded effect sizes and patient heterogeneity can lead to volatility in patient response rates on active drug," the analysts wrote in a note to clients.
The licensing agreement between the two companies dates to 2023, when J&J paid $50 million upfront and committed up to $1 billion in milestone payments for global rights to the M1 receptor (搜索) antagonist. The deal also included a $25 million equity stake and royalties. Contineum, then operating as Pipeline Therapeutics, had completed two Phase 1 trials of the candidate before handing mid-stage development responsibilities to J&J.
Market Reaction
Despite the clinical setback, the market response was relatively measured. Contineum shares fell about 3.5% to $14.30 in after-hours trading, according to one report, while other sources cited declines of 8% to 10% in the immediate aftermath of the announcement. The stock has gained approximately 30% year-to-date, and J&J shares traded flat after hours.
From a technical standpoint, Contineum's chart had been constructive before the news. The stock maintained a bullish 20-day-over-50-day moving average alignment and a golden cross dating back to September 2025, with the 50-day simple moving average positioned above the 200-day. The 52-week range spans $8.60 to $17.79, with the high set in September. Key resistance sits near $15.34, close to the 50-day moving average, while support aligns with the 200-day moving average around $13.60.
PIPE-791 Becomes the Central Narrative
With two efficacy misses now on the books for PIPE-307, analysts say most of Contineum's value is tied to PIPE-791, an LPA1 receptor (搜索) antagonist the company is developing independently for idiopathic pulmonary fibrosis (搜索) and chronic pain (搜索). The candidate is positioned as a potential rival to Bristol Myers Squibb (搜索)'s admilparant, which is further along in development.
The PROPEL-IPF trial, a global mid-stage study of approximately 324 patients, began dosing in the first quarter of 2026. It measures change in lung function over 26 weeks across more than 55 sites in eight countries, with completion not expected until mid-2028. Contineum has deferred a progressive-MS effort for PIPE-791 and paused another early-stage program, CTX-343.
William Blair analysts identified the next key catalyst for Contineum shares as readthrough from Phase 3 data on Bristol Myers Squibb (搜索)'s admilparant, which the company is expected to share early in the fourth quarter. Contineum reported cash of $236.6 million as of June 30, which the company says funds operations through mid-2029, past the planned IPF readout.